Hepatitis clinical trials at UC Davis
1 in progress, 0 open to eligible people
Showing trials for
Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
Sorry, not currently recruiting here
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.
Sacramento, California and other locations
Last updated: